Collaborative Development

Gentel has collaborated with a wide variety of academic and commercial entities to develop new technologies and products. These efforts have been bolstered in the past four years by more than $2 million in research funding awarded to by the National Institutes of Health and other federal agencies. Our first-class scientific staff and cutting-edge instrumentation and facilities enable us to rapidly develop technology from concept-to-product.

Our scientists can accelerate your progress by developing protein microarrays, surface chemistry configurations, and assay platforms to meet your needs. These solutions can be integrated with our fully automated, high-throughput platform for quantitation of proteins in human serum, plasma, urine, saliva, and a variety of tissue and cell lysates. Your data will be obtained using a comprehensive high-throughput platform developed and validated in collaboration with major pharmaceutical companies for use in clinical trial monitoring.

Gentel is continually seeking to develop new-to-the-world protein assays with partners that have access to unique, market-driven, high-quality protein content such as antibodies, antigens, functional enzymes or recombinant proteins. We specialize in developing disease-themed assays where more than four proteins are involved. For more information, contact us at info@gentelbio.com.